United States · Bill · S
S. 1250 (118th)
Drug-price Transparency for Consumers Act of 2023
Introduced
20 April 2023
Last action
—
Status
Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S1297; text: CR S1297-1298)
Sponsors
—
Subjects
Discovery layer
Source updated
5 December 2025
Summary
Drug-price Transparency for Consumers Act of 2023 or the DTC Act of 202 3 This bill requires consumer advertisements for drugs and biologicals to include certain price information if the drug or biological is (1) covered under Medicare or Medicaid, and (2) required to include a risk summary under current law. The requirement does not apply to advertisements for drugs or biologicals with a wholesale cost of less than $35 for a one-month supply. Each violation of this requirement is subject to a civil penalty of not more than $100,000.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in Senate (text)
Introduced in Senate (text)
Introduced in Senate · EN · 20 April 2023
Introduced in Senate (PDF)
Introduced in Senate · EN · 20 April 2023
Introduced in Senate
summary · EN · 20 April 2023
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/118th-congress/senate-bill/1250
- Open data entity: https://api.congress.gov/v3/bill/118/s/1250